Malin investors urged to reject executive pay deal
Series of investments in life science companies have been badly received by the market
Malin-backed Melinta gets Nasdaq listing after merger with Cempra
Melinta Therapeutics is Malin’s second-largest investment by capital committed
One More Thing: Ingram in Valeant hot seat
Hospitalisation of Mike Pearson saw firm split his roles and bring Ingram to the chair
Malin invests $35m in Melinta in first post-IPO asset
Irish life sciences firm also commits further $10m in company
State-backed fund expected to back Malin IPO
Britsh fund manager Neil Woodford also purchasing shares
Elan gene pool continues to deliver
Elan executives turn their sights to funding side of biotech/life sciences business
Ireland’s Malin seeks up to €325m in biotech IPO
Former Elan boss Kelly Martin and chairman Bob Ingram to sit on company’s board
Failure of Royalty Pharma bid likely to hit Elan share price, say analysts
Fate of $6.7bn offer will be decided by shareholders at extraordinary general meeting on Monday
Irish-based Royalty Pharma are already a major player in field
Founded in 1996, it built a major business by procuring the rights to royalties of some of the major drugs in the market, including Humira, Januvia, Lyrica and Remicade
Elan says it has ‘Plan B’ if shareholders reject deals
Royalty Pharma last week increased hostile cash bid for Elan
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices